Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Mar 13
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
ABSTRACT
.
Related Questions
New answer by Medical Oncologist at Cleveland Clinic (March 26, 2024)
I typically order upfront NGS testing at the time of HR+/HER2- metastatic breast cancer diagnosis with the idea that I will have the PIK3CA mutation information already availa...